EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2023 • Aprea Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS EMPLOYMENT AGREEMENT (the “Agreement”) between APREA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and Eyal C. Attar, M.D. (the “Executive”), is made and entered into as of September 26, 2019, and will become effective, if at all, upon the date of closing of the Company’s initial public offering of stock pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
SEPARATION AND GENERAL RELEASE AGREEMENTSeparation and General Release Agreement • March 30th, 2023 • Aprea Therapeutics, Inc. • Pharmaceutical preparations
This Separation and General Release Agreement (the “Agreement”) is made by and between Lars Abrahmsen (the “Executive”) and Aprea Therapeutics, Inc. (the “Company”) (collectively, the “Parties”).
March 28, 2023 Via Email Greg Korbel greg.korbel@gmail.com Dear Greg:Aprea Therapeutics, Inc. • March 30th, 2023 • Pharmaceutical preparations • Pennsylvania
This Separation Agreement and General Release (this “Agreement”) will confirm the arrangements we have discussed concerning the mutual understanding reached by Aprea Therapeutics, Inc. (the “Company”) and you regarding the cessation of your employment. Subject to your execution and non-revocation of this Agreement, your last day of work with the Company will be and your employment with the Company will end on March 31, 2023 (the “Separation Date”). Capitalized terms used herein and not otherwise defined have the meanings ascribed to such terms in the Employment Agreement by and between you and the Company dated as of July 15, 2016 (as amended, modified, or restated from time to time, the “Employment Agreement”).
CONFIDENTIAL SEVERANCE AGREEMENT AND GENERAL RELEASEConfidential Severance Agreement and General Release • March 30th, 2023 • Aprea Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Confidential Severance Agreement and General Release (“Agreement”) is made by and between Scott M. Coiante (“Employee”) and Aprea Therapeutics, Inc., its subsidiaries, affiliates, successors, and assigns (“Company”) (collectively, the “Parties”).
